
In the CANVAS Program and CREDENCE trials, the sodium-glucose co‐transporter two inhibitor canagliflozin reduced the risk of cardiovascular and kidney events in patients with type 2 diabetes. The current study analyzed a pooled population to ascertain the kidney protection canagliflozin provides across the full spectrum of kidney parameters. In the overall population, the primary kidney composite outcome risk was 37% lower in the canagliflozin group versus placebo. These results emphasize the critical role of canagliflozin in kidney protection across a broad spectrum of participants with type 2 diabetes with varying levels of kidney function.
Like
Save
Share